Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: GlobeNewswire
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give an oral presentation at the Retinal Therapeutics Innovation Summit being held on May 1, 2026, in Denver, Colorado. The presentation will cover the previously disclosed positive topline results from the Phase 3 DRAGON trial, which evaluated tinlarebant for the treatment of Stargardt disease type 1 (STGD1). In the study, tinlarebant demonstrated a clinically meaningful 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo along with a strong safety profile. The presentation will be followed by a brief question and answer session. Presentation DetailsSession: Small Molecules to the RescueTitle: Topline Results from a 2-year
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference [Yahoo! Finance]Yahoo! Finance
- Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference Transcript [Seeking Alpha]Seeking Alpha
- Prevent Blindness Declares May as Third Annual Inherited Retinal Disease and Genetic Testing Month, Offering Resources to Public and Healthcare Allies, to Help Save SightPR Newswire
- How Belite Bio's (BLTE) Rolling FDA NDA For Tinlarebant Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Belite Bio to Participate in Four Upcoming Investor ConferencesGlobeNewswire
BLTE
Earnings
- 3/2/26 - Beat
BLTE
Sec Filings
- 4/29/26 - Form 4
- 4/28/26 - Form 4
- 4/27/26 - Form 4
- BLTE's page on the SEC website